SPARQL
Downloads
Documentation/Help
Skip Header
Results
Your Query
Add common prefixes
DESCRIBE <http://purl.uniprot.org/SHA-384/FEEDAE71543E798B00B850B0153A94FA42D93FD3B084A61021E5B7FE9D79D419AE732B5089B7B4D0B780EDCBC4CEEA10>
Submit Query
Cancel
RDF/XML
NTriples
Turtle
Show query
Share
Subject
Predicate
Object
http://purl.uniprot.org/SHA-384/FEEDAE71543E798B00B850B0153A94FA42D93FD3B084A61021E5B7FE9D79D419AE732B5089B7B4D0B780EDCBC4CEEA10
http://www.w3.org/1999/02/22-rdf-syntax-ns#type
http://purl.uniprot.org/core/Annotation
http://purl.uniprot.org/SHA-384/FEEDAE71543E798B00B850B0153A94FA42D93FD3B084A61021E5B7FE9D79D419AE732B5089B7B4D0B780EDCBC4CEEA10
http://www.w3.org/2000/01/rdf-schema#comment
"Data show that HLA-A24-restricted mammaglobin-A (Mam-A) derived CD8(+) cytotoxic T lymphocyte (CTL) epitopes that can potentially be employed for Mam-A-based breast cancer vaccine therapy to breast cancer patients with HLA-A24 phenotype."
xsd:string
http://purl.uniprot.org/uniprot/#_980B0219270421875E735B630A9F2123B409EF0E6B0F552B2DDC9223609DBFD884BE72D8E456AF94E9D8D16B07380CBA
http://www.w3.org/1999/02/22-rdf-syntax-ns#subject
http://purl.uniprot.org/SHA-384/FEEDAE71543E798B00B850B0153A94FA42D93FD3B084A61021E5B7FE9D79D419AE732B5089B7B4D0B780EDCBC4CEEA10
http://purl.uniprot.org/uniprot/A2Q116
http://purl.uniprot.org/core/mappedAnnotation
http://purl.uniprot.org/SHA-384/FEEDAE71543E798B00B850B0153A94FA42D93FD3B084A61021E5B7FE9D79D419AE732B5089B7B4D0B780EDCBC4CEEA10
http://purl.uniprot.org/uniprot/#_A2Q116-mappedCitation-22074997
http://purl.uniprot.org/core/mappedAnnotation
http://purl.uniprot.org/SHA-384/FEEDAE71543E798B00B850B0153A94FA42D93FD3B084A61021E5B7FE9D79D419AE732B5089B7B4D0B780EDCBC4CEEA10